Literature DB >> 24397352

Are FDA and CE sacrificing safety for a faster commercialization of xenogeneic tissue devices? Unavoidable need for legislation in decellularized tissue manufacturing.

F Naso1, L Iop, M Spina, G Gerosa.   

Abstract

Keywords:  alphaGal; biomaterials; food and drug administration; xenoantigen

Mesh：

Year:  2014        PMID： 24397352     DOI： 10.1111/tan.12275

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN： 0001-2815


× No keyword cloud information.
  3 in total

Review 1.  Can Heart Valve Decellularization Be Standardized? A Review of the Parameters Used for the Quality Control of Decellularization Processes.

Authors:  F Naso; A Gandaglia
Journal:  Front Bioeng Biotechnol       Date:  2022-02-17

Review 2.  Guided tissue regeneration in heart valve replacement: from preclinical research to first-in-human trials.

Authors:  L Iop; G Gerosa
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

3.  Ambiguity in the Presentation of Decellularized Tissue Composition: The Need for Standardized Approaches.

Authors:  Arne A N Bruyneel; Carolyn A Carr
Journal:  Artif Organs       Date:  2016-12-07       Impact factor: 3.094
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.